Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
New formulation of MabThera approved for lymphoma
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Oct 30, 2014 03:16:21
The Ministry of Food and Drug Safety on October 27 approved a new subcutaneous formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma resistant to the current therapies.

Intravenous MabThera takes 2.5 hours for infusion, but subcutaneous MabThera takes only 5 minutes for injection. The dose for subcutaneous MabThera is fixed at 1,400 mg. No adjustment is needed.

Subcutaneous MabThera is known to be as safe as intravenous MabThera. The new formulation will provide convenience for patients and providers.

Roche Korea also introduced subcutaneous Herceptin in May. Intravenous Herceptin takes 1.5 hours, but subcutaneous Herceptin takes only 2-5 minutes.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com